Safety and tolerability through assessment of adverse events, ECGs, vital signs, clinical laboratory variables, MRI of brain and spinal cord, CSF sampling, and device performance as characterized by catheter tip placement and infusion accuracy. Multiple over 3 months [clinicaltrials_resource:089d96cdf1290d7478e93151bab4ca93]
Continuous ICV infusion for two weeks at one of three dose levels
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Safety and tolerability through assessment of adverse events, ECGs, vital signs, clinical laboratory variables, MRI of brain and spinal cord, CSF sampling, and device performance as characterized by catheter tip placement and infusion accuracy. Multiple over 3 months [clinicaltrials_resource:089d96cdf1290d7478e93151bab4ca93]
Continuous ICV infusion for two weeks at one of three dose levels
Bio2RDF identifier
089d96cdf1290d7478e93151bab4ca93
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:089d96cdf1290d7478e93151bab4ca93
measure [clinicaltrials_vocabulary:measure]
Safety and tolerability throug ...... acement and infusion accuracy.
time frame [clinicaltrials_vocabulary:time-frame]
Multiple over 3 months
description
Continuous ICV infusion for two weeks at one of three dose levels
identifier
clinicaltrials_resource:089d96cdf1290d7478e93151bab4ca93
title
Safety and tolerability throug ...... curacy. Multiple over 3 months
@en
type
label
Safety and tolerability throug ...... d96cdf1290d7478e93151bab4ca93]
@en